Sensei Biotherapeutics to present SNS-103 data at conference

Sensei Biotherapeutics, Inc. will present preclinical data on its investigational antibody SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference from September 8-11, 2024, in National Harbor, MD. The research focuses on monoclonal antibodies targeting CD39 in the tumor microenvironment. Sensei is developing several conditionally active therapeutics aimed at enhancing cancer treatment efficacy.